ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
advertisementadvertisement
Cell Biology International
Volume 30, Issue 2, February 2006, Pages 183-189
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (409 K)

 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.cellbi.2005.08.014    How to Cite or Link Using DOI (Opens New Window)
Copyright © 2005 International Federation for Cell Biology Published by Elsevier Ltd.

Inhibition of benzo(a)pyrene-induced cell cycle progression by all-trans retinoic acid partly through cyclin D1/E2F-1 pathway in human embryo lung fibroblasts

Xiaowei Jiaa, Bingci Liua, Corresponding Author Contact Information, E-mail The Corresponding Author, Xianglin Shib, Ai Gaoa, Baorong Youa, Meng Yea, Fuhai Shena and Hongju Dua

aNational Institute of Occupation Health and Poison Control, Chinese Center for Disease Control and Prevention, 29 Nan Wei Road, Beijing 100050, China bInstitute for Nutritional Sciences, SIBS, the Chinese Academy of Sciences, Shanghai 200031, China

Received 14 June 2005; 
revised 2 July 2005; 
accepted 10 August 2005. 
Available online 6 January 2006.

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Abstract

Benzo(a)pyrene [B(a)P] is a potent environmental carcinogen, which induces cell cycle changes. All-trans retinoic acid (ATRA) is a promising agent in prevention and treatment of human cancers. In the present study, we investigated the inhibition of B(a)P-induced cell cycle progression by ATRA in human embryo lung fibroblast (HELF). Our results showed that after treatment with B(a)P, the expression of cyclin D1 and E2F-1 were both increased significantly in HELF. There were almost no changes of CDK4 and E2F-4 expression by treatment with B(a)P. As expected, pretreatment with ATRA could efficiently decrease B(a)P-induced overexpression of cyclin D1 and E2F-1. In a further study, we stably transfected antisense cyclin D1 and antisense CDK4 plasmid into HELF. The inhibition of cyclin D1 expression and the inhibition of CDK4 expression significantly impaired the B(a)P-induced overexpression of E2F-1 respectively. Pretreatment with ATRA, cells expressing antisense cyclinD1 or antisense CDK4 showed a lesser decrease of B(a)P-induced overexpression of E2F-1 compared with similarly treated HELF. Furthermore, flow cytometry analysis showed that B(a)P promoted cell cycle progression from G1 phase to S phase, while pretreatment with ATRA could inhibit B(a)P-induced cell cycle progression by an accumulation of cells in the G1 phase. It was suggested that ATRA could block B(a)P-induced cell cycle promotion partly through the cyclin D1/E2F-1 pathway in HELF.

Keywords: All-trans retinoic acid; Benzo(a)pyrene; Cyclin D1; CDK4; E2F; Cell cycle

Abbreviations: ATRA, all-trans retinoic acid; RA, retinoic acid; B(a)P, benzo(a)pyrene; CDK4, cyclin-dependent kinase 4; pRb, retinoblastoma protein; HELF, human embryo lung fibroblast; FBS, fetal bovine serum; DTT, 1,4-dithiothreitol; SDS, sodium dodecyl sulfate; DMSO, dimethyl sulfoxide

Article Outline

1. Introduction
2. Materials and methods
2.1. Chemicals
2.2. Cell lines and treatment with chemicals
2.3. Generation of stable transfectants
2.4. Western blot analysis
2.5. Cell cycle analysis
2.6. Statistical analysis
3. Results
3.1. B(a)P increased levels of cyclin D1 and E2F-1
3.2. Pretreatment with ATRA blocked B(a)P-induced overexpression of cyclin D1 and E2F-1 in HELF
3.3. Treatment with antisense of cyclin D1 and antisense CDK4
3.4. Pretreatment with ATRA blocked B(a)P-induced cell cycle progression
4. Discussion
Acknowledgements
References




Cell Biology International
Volume 30, Issue 2, February 2006, Pages 183-189
 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy
Copyright © 2008 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.